U.S. Markets close in 3 hrs 45 mins

Pernix Therapeutics Holdings, Inc. (PTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.97+0.04 (+1.37%)
As of 12:09PM EDT. Market open.
People also watch
EBIOXGTISKLNSPHSIMNP
  • B
    Bruno
    Bruno
    $3.00 ~ Current Price
    $30.00 ~ 1 Year Price Target
    "Let's get a move on it."
  • C
    Carlos
    Carlos
    In the stock market, never wait too long because their goals is to take your money not to give you. PTX is a high risk company and has little chance of big winnings.
  • C
    Carlos
    Carlos
    Down, down, down. I repeat, this management is a scam for small investors. $2 before 2018!
  • C
    Carlos
    Carlos
    If you do not want to lose everything, sell now before it's too late. the next earning $ 2!
  • C
    Carlos
    Carlos
    It smells like a scam for small investors.
  • C
    Carlos
    Carlos
    $2 arrive. It is obvious!
  • C
    Carlos
    Carlos
    Nothing positive until 2018-2019 (MAYBE)
  • M
    Morgan
    Morgan
    Is PTX undervalued? This sort of setup suggests potential upside... Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from Awe.Some.Sto-ck.s.
  • r
    richard
    richard

    Micro Cap News Alert: NEW ENERGY SOURCE - Startup - Clean Energy Technologies (CETY) buys General Electric “Heat Recovery Systems Division” and within 2 years achieves break-even with sales now set to soar and to be profitable.

    CETY announced today the launch of Pacific Rim Initiative with over 20 locations already identified by CETY and PPA power company authorities.

    Early orders just from Pacific Rim likely to exceed $25 million in annuitized sales. 12-month target price $.25

    CETY/GE proprietary oil-free magnetic levitation turbine technology shatters the competition’s old oil-lubricated screw expander technologies.

    Company expects to up list to NASDAQ.

    CETY's implementation includes creative lease financing structure, that facilitates rapid adoption and ease of entry with long-term payment structure that allows the utility user to align its investment with actual energy and cost savings realized through use of Clean Cycle™ units," said Kam Mahdi, CEO of CETY.

    CETY being welcomed with red carpet to largest markets in the world in need of clean energy.

    Watch for new announcements coming soon!

    https://finance.yahoo.com/news/clean-energy-technologies-cety-launches-131500960.html

    Clean Energy Technologies (CETY) Launches Pacific Rim Initiative
    COSTA MESA, Calif. , Aug. 15, 2017 Clean Energy Technologies, Inc. (OTC: CETY) announced that CETY officially launched its new campaign to deliver its energy solutions to Island Nations utilities at the ...
    finance.yahoo.com
  • C
    Carlos
    Carlos
    In red at the end!
  • J
    Jeremy
    Jeremy

    Success🌱and🌱failure🌱are🌱interwined.🌱 http://dataunion.tistory.com/2996

    Pernix Therapeutics Holdings Inc NASDAQ : PTX Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.2 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • C
    Carlos
    Carlos
    PTX starts its dives. Below $2 arrive
  • B
    Blumenthal
    Blumenthal

    SLNO (MC $27 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market /NO Debt = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $27 Million
    Cash: $8 Million
    Price $0.59

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • E
    Emily
    Emily
    The trading setup for PTX looks very enticing. check out awesome*sto-cks, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
  • J
    JBSINC
    JBSINC
    PTX, getting up
  • C
    Carlos
    Carlos
    Yoyo today. Above or under 3?
  • C
    Carlos
    Carlos
    Here we go under $2
  • T
    Thiepe
    Thiepe
    Nice rebound today
  • K
    Kiley
    Kiley
    T0pMarketGaIners.c0m is one of the best “alerts” services I have found. Just sign up and watch from the sidelines, you will see!
  • C
    Carlos
    Carlos
    It's Friday, taking profit for the trader!